Principal
Inbal Michailovici joined Arkin Bio Ventures as a Principal in 2023. Inbal is part of the ABV3 management team, an early-stage fund focused on seed and Series A breakthrough technologies. With an entrepreneurial mindset, she brings a wealth of experience in company creation and tech evaluation.
Before joining Arkin, Inbal was the Head of Search & Evaluation and Company Creation at the biotech incubator, FutuRx. Prior to FutuRx, she led the Hematology & New Therapeutic Areas at Medison Ventures and served as a Business Development Manager at BiolineRx. Her roles included global scouting, scientific and commercial evaluation, in-licensing, investments, venture creation, and portfolio management.
Inbal holds a Ph.D. from the Weizmann Institute of Science in the field of signal transduction and embryonic muscle development.
Let’s get in touch!
